fda warning glp-1 compounding september 2025 Sends Letters to More Than 50 Compounders and Manufacturers US FDA clarifies policies on

HEALOR publishes its specific compound list rather than hiding behind custom protocols language, which makes it easier for patients to confirm whether the clinic actually carries what they need

Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the scale insulin randomized controlled trial

Activation of GLP-1R signaling promotes M2-like macrophage phenotype while inhibiting M1-like macrophages across various models

10.1046/j.1365-313X.2003.01901.x Plant J

In FAERS, this GLP-1 RA showed a notable connection with diabetic retinopathy, but its effect was not as prominent in other conditions when compared to other drugs like insulin